Answers are grounded in this paper and cite their sources.
Background Resistance to ALK tyrosine kinase inhibitors (ALK-TKIs) remains a major challenge in the management of advanced ALK-rearranged non-small cell lung cancer (NSCLC), with limited understanding of longitudinal molecular changes under sequential therapy. Case Description We report a 45-year-old never-smoker man with advanced NSCLC harboring an EML4–ALK (E18:A20) fusion, a TP53 p.H179R mutation, and 11q13.3 amplification (copy number >4; including CCND1, FGF19, FGF3, and FGF4). The patient received pemetrexed–carboplatin chemotherapy followed by sequential ALK-TKI therapy. Tissue-based next-generation sequencing (NGS) at disease progression in March 2021 detected ALK p.E1210K (VAF 7.24%). In a subsequent lung biopsy obtained on 16 June 2023, ALK p.E1210K was not detected in the subsequent specimen, whereas a putative ANK3–RET rearrangement was detected at a VAF of 14.02%. Pralsetinib (400 mg once daily) plus lorlatinib (100 mg once daily) was administered from July 2023 to October 2023, but progressive disease was documented. Conclusion Serial tissue-based NGS documented longitudinal changes in resistance-associated molecular findings across multiple stages of treatment. The changing detection status of ALK p.E1210K and detection of a putative ANK3–RET rearrangement may reflect treatment-related selection, spatial heterogeneity, differences in biopsy sites and tumor content, or assay sensitivity. Because the later ANK3–RET finding was identified by DNA-based NGS without RNA-level or orthogonal validation, its breakpoint, reading frame, transcript expression, and retention of the RET kinase domain could not be established. The lack of disease control with pralsetinib plus lorlatinib further limits interpretation of ANK3–RET as a clinically actionable resistance-associated event. These findings therefore document longitudinal molecular changes rather than confirmed clonal evolution or a definitive transition from ALK-dependent to ALK-independent resistance, and caution against acting on unvalidated DNA-based fusion calls in clinical practice.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: